Key facts
- GPN Vaccines’s last known valuation is $300.0M (Jun 2024).
- It has raised $27.7M across 1 recorded rounds; the latest was Seed Round ($3.5M) in Dec 2025.
- Notable investors include Shearwater Capital, Brandon Biocatalyst, Forepont Capital Partners, Kern Capital, Mike Gregg — 7 tracked in total.
- GPN Vaccines has filed 1 Form D with the SEC, most recently Jan 2026 ($3.5M sold to 63 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for GPN Vaccines
Funding rounds
1 roundsAbout GPN Vaccines
Developer of vaccines intended to offer protection against pneumococcal bacteria, the world's foremost bacterial pathogen. The company's vaccine is developed by using a gamma-irradiation process that inactivates and kills the bacteria while leaving the surface protein antigens intact, thereby conferring improved immunity against Streptococcus pneumoniae, giving patients the chance of improved immunity against Streptococcus pneumoniae.
- Sector
- Healthcare
- HQ
- Canberra, Australia
- Founded
- 2017
- Employees
- 28
- Website
- gpnvaccines.com/
- Ownership
- Privately Held (backing)
GPN Vaccines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GPN Vaccines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GPN Vaccines in its N-PORT filings yet. We sweep new filings monthly.